Latest News

Navidea Biopharmaceuticals Announces Reverse Stock Split

DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a one-for-twenty reverse stock split of its issued and outstanding shares of common stock. The reverse split will be effective at 12:01 a.m. (EDT) on April 26, 2019, and shares of the Company’s common stock will begin trading on

Source link

Related posts

Drug that treat human breast cancer might also work for canine lung cancer


1 in 6 Hospital, ER Stays Result in Surprise Bills


Zimbabwe's Wildlife Severely Affected By Dry Weather


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy